Search results for "olanzapine"

showing 10 items of 32 documents

Attitudes toward Different Formulations of Psychotropic Drugs

2006

Attitudes toward psychotropic drug treatment are likely to be a factor in medication adherence and outcome, but preferences regarding different drug formulations have been rarely assessed. To explore attitudes toward different drug formulations in a cross-sectional study in psychiatric patients and a comparison group of healthcare professionals. Inpatients (n = 59, age 46 ± 14 years, 63% female) and staff members (n = 96, age 40 ± 10 years, 65% female) of a psychiatric department were surveyed using a questionnaire on attitudes toward 18 possible application forms of psychotropic drugs including newer formulations such as fast-dissolving tablets. The questionnaire asked respondents to rate …

PharmacologyDrugOlanzapinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectAlternative medicineMedication adherencePharmacyPharmacologyPreferencePsychotropic drugmedicineZiprasidonebusinessmedia_commonmedicine.drugClinical psychologyAmerican Journal of Drug Delivery
researchProduct

Psychopharmacological treatment of bipolar disorder in Latin American

2011

Abstract Objective This study assessed the treatment preferences among Latin American psychiatrists for their bipolar disorder patients and if these preferences reflect the current guidelines. Methods We designed a survey comprised of 14 questions. All the questions were aimed at the treatment of bipolar I patients only. We distributed the survey by hand or e-mail to psychiatrists in eight different countries: Argentina, Brazil, Colombia, Costa Rica, Ecuador, Mexico, Peru and Venezuela. Between May 2008 and June 2009, we were able to gather 1143 surveys. Results As the initial choice of treatment for a bipolar patient who debuts with mania, 61.3% choose a combination of an atypical antipsyc…

Olanzapinemedicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticMood stabilizerGeneral MedicineLamotriginemedicine.diseasebehavioral disciplines and activitiesTreatment of bipolar disordermental disordersMedicineBipolar disordermedicine.symptombusinessPsychiatryAntipsychoticManiamedicine.drugClinical psychologyRevista de Psiquiatría y Salud Mental (English Edition)
researchProduct

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs

2009

Studies conducted to obtain drug authorization are often of short duration and based on small sample sizes in selected populations. Policies on drug safety rely on the validity of the methods used to achieve rapid and effective communication of new information. No formal evaluation has ever been made of the Spanish communications system, although indirect data have raised questions about its effectiveness.To evaluate the impact of two safety warnings issued by the Spanish Drug Agency, and of a later prior authorization requirement involving the use of atypical antipsychotic drugs in the elderly.The study was based on a time-series analysis constructed with data corresponding to monthly invo…

Olanzapinemedicine.medical_specialtymedicine.drug_classAtypical antipsychoticToxicologyCommunications systemInterrupted Time Series AnalysisBenzodiazepinesmedicineHumansPharmacology (medical)ZiprasidoneAmisulpridePractice Patterns Physicians'Medical prescriptionPsychiatryAgedPharmacologyRisperidoneDose-Response Relationship DrugInformation Disseminationbusiness.industryRisperidonemedicine.diseaseOlanzapineSpainDrug and Narcotic ControlDementiaMedical emergencybusinessAntipsychotic Agentsmedicine.drugDrug Safety
researchProduct

Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection

2005

An isocratic high-performance liquid chromatography (HPLC) method with column switching and ultraviolet (UV) detection is described for quantitative analysis of the new antipsychotic drug ziprasidone. After centrifugation of serum or plasma samples and addition of fluperlapine as internal standard, the samples were injected into the HPLC system. On-line sample clean-up was conducted on a column (10 x 4.0 mm ID) filled with silica C8 material (20-microm particle size) using 8% (vol/vol) acetonitrile in deionized water as eluent. Ziprasidone was eluted and separated on ODS Hypersil C18 material (5 microm; column size 250 x 4.6 mm ID) using acetonitrile-water-tetramethylethylendiamine (50:49.6…

AdultMaleTime FactorsSensitivity and SpecificityHigh-performance liquid chromatographyDrug Administration SchedulePiperazinesAutomationBenzodiazepinesBlood serumColumn chromatographymedicineHumansPharmacology (medical)ZiprasidoneClozapineChromatography High Pressure LiquidPharmacologyDetection limitChromatographymedicine.diagnostic_testElutionChemistryReproducibility of ResultsMiddle AgedThiazolesOlanzapineSpectrophotometryTherapeutic drug monitoringSchizophreniaFemaleDrug MonitoringQuantitative analysis (chemistry)medicine.drugTherapeutic Drug Monitoring
researchProduct

Synthesis and Oxidant Properties of Phase 1 Benzepine N-Oxides of Common Antipsychotic Drugs

2013

There is increasing evidence that cell constituents are oxidized by widely used antipsychotic drugs but until now the underlying chemistry has remained unclear. It is well known that such drugs readily undergo N-oxidation as a first key metabolic step. To gain insight into the problem, the tertiary phase 1 N-oxides of clozapine, olanzapine, quetiapine, and zotepine were synthesized, together with the N,S-dioxides of quetiapine and zotepine. These N-oxides were then subjected to well-established chemical transformations to test their oxidant properties in group VIII transition-metal­-catalyzed reactions. In the osmium tetroxide catalyzed dihydroxylation of styrene or cinnamyl alcohol and in …

OlanzapineCinnamyl alcoholChemistryOrganic ChemistryRedoxCatalysischemistry.chemical_compoundTetrapropylammonium perruthenateZotepineDihydroxylationmedicineOrganic chemistryQuetiapineClozapinemedicine.drugSynthesis
researchProduct

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-…

2016

ObjectivesTo meta-analytically summarize lamotrigine’s effectiveness and safety in unipolar and bipolar depression.MethodsWe conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs).ResultsEighteen studies (n=2152, duration=9.83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation …

Olanzapinemedicine.medical_specialtyBipolar DisorderLithium (medication)Bipolar depressionBipolar depression bipolar disorder lamotrigine major depressive disorder trials unipolar depressionCitalopramLithiumCitalopramLamotrigineLamotriginePlaceboBipolar depression; bipolar disorder; lamotrigine; major depressive disorder; trials; unipolar depressionBenzodiazepines03 medical and health sciences0302 clinical medicineAntimanic AgentsFluoxetineInternal medicinemedicineHumansBipolar disorderunipolar depressionPsychiatryDepressive Disorder MajorFluoxetinemajor depressive disorderDepressionTriazinesbusiness.industrytrialsmedicine.diseaseAntidepressive Agents030227 psychiatryDrug CombinationsPsychiatry and Mental healthVitamin B ComplexMajor depressive disorderAnticonvulsantsNeurology (clinical)businessInositol030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Solid microcrystalline dispersion films as a new strategy to improve the dissolution rate of poorly water soluble drugs: A case study using olanzapine

2016

In this study, we evaluate the dissolution rate enhancement of solid microcrystalline dispersion (SMD) films of olanzapine (OLZ) formulated with four water-soluble polymers namely poly(N-vinylpyrrolidone) (PVP), poloxamer 188 (P188), poloxamer 407 (P407) and Soluplus(®) (SLP). Prepared formulations were characterised to determine particle size, morphology, hydrogen bonding interactions, thermal characteristics as well as in vitro dissolution studies conducted under sink conditions (pH 6.8). Particle size of OLZ in all formulations ranged between 42 and 58μm. Attenuated Total Reflectance Fourier Transform Infrared spectroscopy (ATR-FTIR), Differential Scanning Calorimetry (DSC) and Hot-Stage…

3003PVPDrug CompoundingSolid microcrystalline dispersionPharmaceutical SciencePoloxamer02 engineering and technologyPolyethylene Glycol030226 pharmacology & pharmacyPolyethylene GlycolsBenzodiazepines03 medical and health sciences0302 clinical medicineDifferential scanning calorimetrymedicineParticle SizePyrrolidinoneSolubilityFourier transform infrared spectroscopyPolymerPolyvinylDissolutionPharmaceutical filmBenzodiazepineChromatographyCrystallineChemistryHydrogen BondingPoloxamer021001 nanoscience & nanotechnologyPyrrolidinonesDrug LiberationMicrocrystallineSolubilityChemical engineeringOlanzapinePoloxamer 407PolyvinylsParticle sizeCrystallization0210 nano-technologymedicine.drugInternational Journal of Pharmaceutics
researchProduct

Low concentration of ziprasidone in human milk: a case report

2009

Although second-generation antipsychotics are established as the first-line treatment for schizophrenia, female patients are often excluded from this efficient treatment for safety reasons in pregnancy or whilst breastfeeding. For this reason, research on this subject mostly relies on case reports, although there is a great need to establish modern guidelines for treatment. Milk-to-plasma (M:P) ratios have been reported for clozapine (2.79–4.32; Winans, 2001), olanzapine (0.10–0.84; Gardiner et al. 2003), risperidone/9-OH risperidone (0.10–0.42/0.24–0.50; Gentile, 2004) and aripiprazole (0.18–0.20; Schlotterbeck et al. 2007). According to one case report, the infant ingests 0.09–0.43% of th…

PharmacologyOlanzapinemedicine.medical_specialtyPediatricsRisperidonebusiness.industryBreastfeedingPsychiatry and Mental healthPsychiatric historymedicinePsychiatric hospitalQuetiapinePharmacology (medical)AripiprazoleZiprasidonebusinessPsychiatrymedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Hyaluronan Graft Copolymers Bearing Fatty-Acid Residues as Self-Assembling Nanoparticles for Olanzapine Delivery

2019

In order to evaluate the potential of a technology platform based on hyaluronan copolymers grafted with propargylated ferulate fluorophores (HA-FA-Pg) in the development of drug delivery systems, the propargyl groups of HA-FA-Pg derivatives were employed with oleic acid (OA) or stearic acid (SA) residues across a biocompatible hexa(ethylene glycol) (HEG) spacer. The designed materials (i.e., HA-FA-HEG-OA or HA-FA-HEG-SA) showed clear-cut aggregation features in an aqueous environment, as confirmed by dynamic light scattering (DLS) and transmission electron microscopy (TEM), generating nanoaggregate systems. In fact, HA-FA-HEG-OA and HA-FA-HEG-SA derivatives showed the property to create sel…

olanzapinePharmaceutical Science02 engineering and technologyself-assembling nanocarrier010402 general chemistry01 natural sciencesArticlechemistry.chemical_compounddrug delivery systemsDynamic light scatteringhyaluronic acidCopolymerSide chainSolubilityDrug delivery systems; Ferulic acid; Hyaluronic acid; Olanzapine; Oleic acid; Self-assembling nanocarriers; Stearic acidSelf-assembling nanocarriersstearic acid021001 nanoscience & nanotechnology0104 chemical sciencesOleic acidchemistryChemical engineeringoleic acidDrug deliveryStearic acid0210 nano-technologyEthylene glycolferulic acid
researchProduct

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.

2002

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% (0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng…

OlanzapineAdultMaleTime FactorsCombination therapyFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsmedicineHumansPharmacology (medical)Drug InteractionsProspective Studiesmedicine.diagnostic_testbusiness.industryDopamine antagonistPirenzepineDrug interactionMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringChemotherapy AdjuvantFluvoxamineOlanzapineChronic DiseaseSchizophreniaFemalebusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugFollow-Up StudiesJournal of clinical psychopharmacology
researchProduct